REGENXBIO - Stock Price History | RGNX
Historical daily share price chart and data for REGENXBIO since 2023 adjusted for splits. The latest closing stock price for REGENXBIO as of February 03, 2023 is 23.75.
- The all-time high REGENXBIO stock closing price was 82.15 on July 10, 2018.
- The REGENXBIO 52-week high stock price is 35.73, which is 50.4% above the current share price.
- The REGENXBIO 52-week low stock price is 18.69, which is 21.3% below the current share price.
- The average REGENXBIO stock price for the last 52 weeks is 25.89.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
| REGENXBIO Historical Annual Stock Price Data |
| Year |
Average Stock Price |
Year Open |
Year High |
Year Low |
Year Close |
Annual % Change |
| 2022 |
26.2713 |
34.3100 |
35.0400 |
19.3500 |
22.6800 |
-30.64% |
| 2021 |
37.0514 |
44.9700 |
49.9500 |
29.0900 |
32.7000 |
-27.91% |
| 2020 |
36.5798 |
38.9900 |
54.2000 |
21.5000 |
45.3600 |
10.72% |
| 2019 |
44.7959 |
43.3300 |
62.4500 |
31.8400 |
40.9700 |
-2.34% |
| 2018 |
52.0580 |
34.7500 |
82.1500 |
24.0500 |
41.9500 |
26.17% |
| 2017 |
22.8349 |
18.5000 |
34.6000 |
16.7000 |
33.2500 |
79.25% |
| 2016 |
13.4967 |
17.0000 |
24.0000 |
7.3200 |
18.5500 |
11.75% |
| 2015 |
20.6147 |
30.4500 |
30.7000 |
14.1500 |
16.6000 |
0.00% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$1.028B |
$0.470B |
|
REGENXBIO Inc. is a biotechnology company. The Company focuses on the development, commercialization and licensing of recombinant adeno-associated virus gene therapy. Its products candidates include RGX-501, for the treatment of homozygous familial hypercholesterolemia which uses the AAV8 vector to deliver the human low-density lipoprotein receptor gene to liver cells; RGX-111, for the treatment of Mucopolysaccharidosis Type I which uses the AAV9 vector to deliver the human a-l-iduronidase gene to the central nervous system; RGX-121, for the treatment of Mucopolysaccharidosis Type II; RGX-314, for the treatment of wet age-related macular degeneration and RGX-321, for the treatment of X-linked retinitis pigmentosa. REGENXBIO Inc. is headquartered in Rockville, Maryland.
|
